相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Prognostic Significance of Androgen Receptor Expression in Triple Negative Breast Cancer: A Systematic Review and Meta-Analysis
Meng Xu et al.
CLINICAL BREAST CANCER (2020)
Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory
Mauro Poggio et al.
CELL (2019)
CALGB (Alliance) 40603: Long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) plus /- carboplatin (Cb) and bevacizumab (Bev) in triple-negative breast cancer (TNBC).
William M. Sikov et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
The Multifaceted p21 (Cip1/Waf1/CDKN1A) in Cell Differentiation, Migration and Cancer Therapy
Nina-Naomi Kreis et al.
CANCERS (2019)
Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review
Jessa Gilda P. Pandy et al.
BMC CANCER (2019)
CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer
Zi-Ming Zhao et al.
BMC CANCER (2019)
Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial
Andreas Schneeweiss et al.
EUROPEAN JOURNAL OF CANCER (2019)
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype
L. Gerratana et al.
CANCER TREATMENT REVIEWS (2018)
The clinical promise of immunotherapy in triple-negative breast cancer
Praveen Vikas et al.
CANCER MANAGEMENT AND RESEARCH (2018)
Prognostic significance of p16 & p53 immunohistochemical expression in triple negative breast cancer
Atif Ali Hashmi et al.
BMC CLINICAL PATHOLOGY (2018)
The survival benefit of neoadjuvant chemotherapy and pCR among patients with advanced stage triple negative breast cancer
Tithi Biswas et al.
ONCOTARGET (2017)
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
Gunter von Minckwitz et al.
LANCET ONCOLOGY (2014)
PD-L1 Expression in Triple-Negative Breast Cancer
Elizabeth A. Mittendorf et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Triple negative breast cancer: Clinical characteristics in the different histological subtypes
Geertje Dreyer et al.
BREAST (2013)
The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer
S. Muenst et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
p16 expression correlates with basal-like triple-negative breast carcinoma
Amany A. Abou-Bakr et al.
ECANCERMEDICALSCIENCE (2013)
Triple-negative breast cancer in the older population
P. Boyle
ANNALS OF ONCOLOGY (2012)
High ERK Protein Expression Levels Correlate with Shorter Survival in Triple-Negative Breast Cancer Patients
Chandra Bartholomeusz et al.
ONCOLOGIST (2012)
A single-centre chart review exploring the adjusted association between breast cancer phenotype and prognosis
C. Hamm et al.
Current Oncology (2011)
Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer
Aye Aye Thike et al.
MODERN PATHOLOGY (2010)
ErbB2-Mediated Src and Signal Transducer and Activator of Transcription 3 Activation Leads to Transcriptional Up-Regulation of p21Cip1 and Chemoresistance in Breast Cancer Cells
Valerie S. Hawthorne et al.
MOLECULAR CANCER RESEARCH (2009)
Weekly paclitaxel in the adjuvant treatment of breast cancer
Joseph A. Sparano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study
Lisa A. Carey et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Neoadjuvant versus adjuvant systemic treatment in breast cancer: A meta-analysis
D Mauri et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of intergroup trial C9741/cancer and leukemia group B trial 9741
ML Citron et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
分享论文
